Loading...
Nucleoside analogues, which inhibit herpes simplex virus (HSV) DNA polymerase following phosphorylation by the viral thymidine kinase, have been a mainstay in the treatment and prevention of genital HSV-2 infections. These agents have limitations, however, including development of resistance and inability to reduce viral shedding.
Pritelivir, the first in a new class of antiviral agents, inhibits HSV replication by targeting the viral helicase–primase complex. It has shown potent in vitro activity, as well as efficacy in infection models; phase I studies have demonstrated no safety issues. Now, in an industry-sponsored, proof-of-concept study conducted at seven sites in the U.S., researchers have evaluated the effect of various doses of prit…